Please assess the completion status of the following clinical trial:

Trial Title: Ibudilast and Withdrawal-Related Dysphoria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 21 and 45~2. Meet DSM-5 criteria for current Moderate-to-Severe AUD~3. Current Heavy Drinking (\> 14 drinks per week for men; \> 7 drinks per week for women), as indicated by self-reported drinking for the 30 days prior to screening~4. Have reliable internet access~Exclusion Criteria:~1. Currently receiving or seeking treatment for AUD\*~2. Past year DSM-5 diagnosis of any substance use disorder other than alcohol or nicotine~3. A lifetime diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder~4. Current use of drugs, other than marijuana, verified by a urine toxicology screen\*~5. Pregnant, nursing, or refusal to use reliable birth control (if female)\*~6. A medical condition that may interfere with safe participation (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension, diabetes, or AST, ALT, or GGT ≥ 3 times upper normal limit)~7. Self-reported recent (i.e. past 30 day) use of medications that are contraindicated with ibudilast\*~8. Non-removable ferromagnetic objects in body~9. Claustrophobia~10. Serious head injury or prolonged period of unconsciousness (\>30 minutes)~    * Participants who meet these criteria at any point during the course of the study (i.e. after randomization) will be withdrawn from the study for safety purposes.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Ibudilast (Type: ACTIVE_COMPARATOR): 20mg BID Days 1-2 50mg BID Days 3-14
- Placebo (Type: PLACEBO_COMPARATOR): Matched to active

Based on this trial design, predict the completion outcome and termination type (if applicable).